Genotypes and viral load of hepatitis C virus among persons attending a voluntary counseling and testing center in Ethiopia

Journal of Medical Virology

Volumn 83, Issue 5, 2011, Pages 776-782

  Abreha, Tesfay ^a,b   Woldeamanuel, Yimtubezinash ^b   Pietsch, Corinna ^c   Maier, Melanie ^c   Asrat, Daniel ^b   Abebe, Almaz ^d   Hailegiorgis, Bereket ^e   Aseffa, Abraham ^a   Liebert, Uwe Gerd ^c  

^a ARMAUER HANSEN RESEARCH INSTITUTE   (Ethiopia)

^b ADDIS ABABA UNIVERSITY   (Ethiopia)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d ETHIOPIAN PUBLIC HEALTH INSTITUTE   (Ethiopia)

^e Regional Laboratory   (Ethiopia)

Author keywords

5' UTR; Ethiopia; Genotypes; HCV; HIV; NS5b gene

Indexed keywords

HEPATITIS C ANTIBODY;

ADULT; ARTICLE; CONTROLLED STUDY; COUNSELING; ETHIOPIA; FEMALE; GENETIC SCREENING; GENOME; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; VIRUS GENE; VIRUS LOAD;

ADULT; AGED; COUNSELING; CROSS-SECTIONAL STUDIES; ETHIOPIA; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MIDDLE AGED; MOLECULAR TYPING; POLYMERASE CHAIN REACTION; PREVALENCE; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

HEPATITIS C VIRUS;

EID: 79952732938     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21788     Document Type: Article

References (44)

1. Aceti A, Taliani G, de Bac C, Sebastiani A. 1990. Anti-HCV false positivity in Malaria. Lancet 336: 1442-1443.
2. Agha S, El-Mashad N, El-Malky M, El-Shony H, El-Sherif MZ, El-Hasan MA, Tanaka Y, Mizokami M. 2006. Prevalence of low positive anti-HCV antibodies in blood donors: Schistosoma mansoni co-infection and possible role of autoantibodies. Microbiol Immunol 50: 447-452.
3. Alter MJ. 2006. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 44: S6-9.
4. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, Kaslow RA, Margolis HS. 1999. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med 341: 556-562.
5. Amarapurkar D. 2000. Natural history of hepatitis C virus infection. J Gastroenterol Hepatol 15: E105-E110.
6. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714.
7. Ayele W, Nokes DJ, Abebe A, Messele T, Dejene A, Enquselassie F, Rinke de Wit TF, Fontanet AL. 2002. Higher prevalence of anti-HCV antibodies among HIV-positive compared to HIV-negative inhabitants of Addis Ababa, Ethiopia. J Med Virol 68: 12-17.
8. Bar-Shany S, Green MS, Swnar E. 1996. False positive tests for anti-hepatitis C antibodies and the problem of notifying blood donors. Int J Epidemiol 25: 674-678.
9. Bonacini M, Lin HJ, Hollinger FB. 2001. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 26: 340-344.
10. Cantaloube JF, Laperche S, Gallian P, Bouchardeau F, de Lamballerie X, de Micco P. 2006. Analysis of the 5' noncoding region versus the NS5b region in genotyping hepatitis C virus isolates from blood donors in france. J Clin Microbiol 44: 2051-2056.
11. Chen Z, Weck KE. 2002. Hepatitis C virus genotyping: Interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol 40: 3127-3134.
12. Chou R, Clark EC, Helfand MH. 2004. Screening for hepatitis C virus infection: A review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 140: 465-479.
13. Colombo M. 1999. Natural history and pathogenesis of hepatitis C virus related hepatocellular carcinoma. J Hepatol 31: 25-30.
14. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot-Peignoux M, Matheron S, Le Moing V, Vachon F, Degott C, Valla D, Marcellin P. 2001. The influence of human immunodeficiency virus coinfection on chronic hepatitis C in injection drug users: A long-term retrospective cohort study. Hepatology 34: 1193-1199.
15. Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. 1993. Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 6: 602-610.
16. Feucht HH, Schroter M, Zollner B, Polywka S, Nolte H, Laufs R. 1997. The influence of age on the prevalence of hepatitis C virus subtypes 1a and 1b. J Infect Dis 175: 685-688.
17. FMOH/HAPCO. 2006. AIDS in Ethiopia-Sixth Report. Federal Ministry of Health/National HIV/AIDS Prevention and Control Office. Addis Ababa: FMOH/HAPCO, 52 pp.
18. George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, Alden B, Pfaller MA, Stapleton JT., 2002. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 31: 154-162.
19. Gretch DR. 1997. Diagnostic tests for hepatitis C. Hepatology 26: 43-47.
20. Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer HJ, Bernstein D, Rizzetto M, Zeuzem S, Pockros PJ, Lin A, Ackrill AM. 2004. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: A randomized study of treatment duration and ribavirin dose. Ann Intern Med 140: 346-355.
21. Jones R, Dunning J, Nelson M. 2005. HIV and hepatitis C co-infection. Int J Clin Pract 59: 1082-1087.
22. Maertens G, Stuyver L. 1997. Genotypes and genetic variation of hepatitis C virus. In: Harrison T, Zuckerman A, editors. The molecular medicine of viral hepatitis. New York: John Wiley and Sons. pp. 183-233.
23. Matthews-Greer JM, Caldito GC, Adley SD, Willis R, Mire AC, Jamison RM, McRae KL, King JW, Chang WL. 2001. Comparison of hepatitis C viral loads in patients with or without human immunodeficiency virus. Clin Diagn Lab Immunol 8: 690-694.
24. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling M-H, Cort S, Albrecht JK. 1998. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 339: 1485-1492.
25. McOmish F, Yap PL, Dow BC, Follett EA, Seed C, Keller AJ, Cobain TJ, Krusius T, Kolho E, Naukkarinen R, Lin C, Lai C, Leong S, Medgyesi GA, Hejjas M, Kiyokawa H, Fukada K, Cuypers T, Saeed AA, Al-Rasheed AM, Lin M, Simmonds P. 1994. Geographical distribution of hepatitis C virus genotypes in blood donors: An international collaborative survey. J Clin Microbiol 32: 884-892.
26. Morice Y, Roulot D, Grando V, Stirnemann J, Gault E, Jeantils V, Bentata M, Jarrousse B, Lortholary O, Pallier C, Deny P. 2001. Phylogenetic analyses confirm the high prevalence of hepatitis C virus (HCV) type 4 in the Seine-Saint-Denis district (France) and indicate seven different HCV-4 subtypes linked to two different epidemiological patterns. J Gen Virol 82: 1001-1012.
27. Mudawi HMY, Smith HM, Fletcher IA, Fedail SS. 2007. Prevalence and Common Genotypes of HCV Infection in Sudanese Patients with Hepatosplenic Schistosomiasis. J Med Virol 79: 1322-1324.
28. Pasquier C, Njouom R, Ayouba A, Dubois M, Sartre MT, Vessiere A, Timba I, Thonnon J, Izopet J, Nerrienet E. 2005. Distribution and heterogeneity of hepatitis C genotypes in hepatitis patients in Cameroon. J Med Virol 77: 390-398.
29. Picchio GR, Nakatsuno M, Boggiano C, Sabbe R, Corti M, Daruich J, Perez-Bianco R, Tezanos-Pinto M, Kokka R, Wilber J, Mosier D. 1997. Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) co-infection. J Med Virol 52: 219-225.
30. Plamondon M, Labbé A, Frost E, Deslandes S, Alves AF, Bastien N, Pepin J. 2007. Hepatitis C virus infection in Guinea-Bissau: A sexually transmitted genotype 2 with parenteral amplification? PLoS ONE 2: e372.
31. Razafindratsimandresy R, Dubot A, Ramarokoto C-E, Iehle C, Soares J-L, Rousset D. 2007. Hepatitis C virus infection and genotypes in Antananarivo, Madagascar. J Med Virol 79: 1082-1088.
32. Ross RS, Viazov S, Roggendorf M. 2007. Genotyping of hepatitis C virus isolates by a new line probe assay using sequence information from both the 5' untranslated and the core regions. J Virol Methods 143: 153-160.
33. Sakugawa H, Nakasone H, Nakayoshi T, Kinjo F, Saito A, Yakabi S, Zukeran H, Miyagi Y, Taira R, Koja K, Uezu T, Kina M, Omine K. 1995. High proportion of false positive reactions among donors with anti-HCV antibodies in a low prevalence area. J Med Virol 46: 334-338.
34. Simmonds P. 1995. Variability of hepatitis C virus. Hepatology 21: 570-583.
35. Simmonds P, Smith DB. 1999. Structural constraints on RNA virus evolution. J Virol 73: 5787-5794.
36. Simmonds P, McOmish F, Yap PL, Chan SW, Lin CK, Dusheiko G, Saeed AA, Holmes EC. 1993. Sequence variability in the 5' non-coding region of hepatitis C virus: Identification of a new virus type and restrictions on sequence diversity. J Gen Virol 74: 661-668.
37. Simmonds P, Bukh J, Combet C, Deleage G, Enomoto N, Feinstone S, Halfon P, Inchauspe G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A. 2005. Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 42: 962-973.
38. Soriano V, Sulkowski M, Bergin C, Hatzakis A, Cacoub P, Katlama C, Cargnel A, Mauss S, Dieterich D, Moreno S, Ferrari C, Poynard T, Rockstroh J. 2002. Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. Aids 16: 813-828.
39. Tamalet C, Colson P, Tissot-Dupont H, Henry M, Tourres C, Tivoli N, Botta D, Ravaux I, Poizot-Martin I, Yahi N. 2003. Genomic and phylogenetic analysis of hepatitis C virus isolates: A survey of 535 strains circulating in southern France. J Med Virol 71: 391-398.
40. Thomas DL, Shih JW, Alter HJ, Vlahov D, Cohn S, Hoover DR, Cheung L, Nelson KE. 1996. Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. J Infect Dis 174: 690-695.
41. WHO. 1999. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 6: 35-47.
42. Xu LZ, Larzul D, Delaporte E, Brechot C, Kremsdorf D. 1994. Hepatitis C virus genotype 4 is highly prevalent in central Africa (Gabon). J Gen Virol 75: 2393-2398.
43. Yoo TW, Donfield S, Lail A, Lynn HS, Daar ES. 2005. Effect of hepatitis C virus (HCV) genotype on HCV and HIV-1 disease. J Infect Dis 191: 4-10.
44. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. 1996. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125: 634-639.